Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-2020 in Mild to Moderate Alzheimer's Disease
NCT06881836Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ONO-2020 in Alzheimer's disease (AD) (3 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Treatment Emergent Adverse Events at 26 weeks, Columbia Suicide Severity Rating Scale at 26 weeks and 1 more. Started Apr 2025; status: completed.
02
Drugs
ONO-2020
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06881836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06881836.